tetano
Editor, Senior Moderator
Vaccine
. 2023 May 11;S0264-410X(23)00383-3.
doi: 10.1016/j.vaccine.2023.03.076. Online ahead of print. Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic
Erin Roberts-McCarthy[SUP] 1 [/SUP], Philip O Buck[SUP] 2 [/SUP], Renae L Smith-Ray[SUP] 3 [/SUP], Nicolas Van de Velde[SUP] 2 [/SUP], Tanya Singh[SUP] 4 [/SUP], James Mansi[SUP] 5 [/SUP], Amy Shah[SUP] 6 [/SUP], Michael Taitel[SUP] 7 [/SUP]
Affiliations
Introduction: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prompted accelerated vaccine development of novel messenger RNA (mRNA)-based vaccines by Moderna and Pfizer, which received FDA Emergency Use Authorization in December 2020. The purpose of this study was to examine trends in primary series administration and multi-dose completion rates with Moderna's mRNA-1273 vaccine administered at a United States retail pharmacy.
Methods: Walgreens pharmacy data were joined to publicly available data sets to examine trends in mRNA-1273 primary series and multi-dose completion across patient race/ethnicity, age, gender, distance to first vaccination, and community characteristics. Eligible patients received their first dose of mRNA-1273 administered by Walgreens between December 18, 2020 and February 28, 2022. Variables significantly associated with on-time second dose (all patients) and third dose (immunocompromised patients) in univariate analyses were included in linear regression models. A subset of patients in selected states were studied to identify differences in early and late vaccine adoption.
Results: Patients (N = 4,870,915) who received ≥ 1 dose of mRNA-1273 were 57.0% White, 52.6% female, and averaged 49.4 years old. Approximately 85% of patients received a second dose during the study period. Factors associated with on-time second dose administration included older age, race/ethnicity, traveling ≤ 10 miles for the first dose, higher community-level health insurance, and residing in areas with low social vulnerability. Only 51.0% of immunocompromised patients received the third dose as recommended. Factors associated with third dose administration included older age, race/ethnicity, and small-town residence. Early adopters accounted for 60.6% of patients. Factors associated with early adoption included older age, race/ethnicity, and metropolitan residence.
Conclusion: Over 80% of patients received their on-time second dose of mRNA-1273 vaccine per CDC recommendations. Patient demographics and community characteristics were associated with vaccine receipt and series completion. Novel approaches to facilitate series completion during a pandemic should be further studied.
Keywords: COVID-19; COVID-19 vaccine; Epidemiology; Moderna; Pharmacy; Public health; mRNA Vaccine; mRNA-1273.
. 2023 May 11;S0264-410X(23)00383-3.
doi: 10.1016/j.vaccine.2023.03.076. Online ahead of print. Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic
Erin Roberts-McCarthy[SUP] 1 [/SUP], Philip O Buck[SUP] 2 [/SUP], Renae L Smith-Ray[SUP] 3 [/SUP], Nicolas Van de Velde[SUP] 2 [/SUP], Tanya Singh[SUP] 4 [/SUP], James Mansi[SUP] 5 [/SUP], Amy Shah[SUP] 6 [/SUP], Michael Taitel[SUP] 7 [/SUP]
Affiliations
- PMID: 37296016
- DOI: 10.1016/j.vaccine.2023.03.076
Introduction: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prompted accelerated vaccine development of novel messenger RNA (mRNA)-based vaccines by Moderna and Pfizer, which received FDA Emergency Use Authorization in December 2020. The purpose of this study was to examine trends in primary series administration and multi-dose completion rates with Moderna's mRNA-1273 vaccine administered at a United States retail pharmacy.
Methods: Walgreens pharmacy data were joined to publicly available data sets to examine trends in mRNA-1273 primary series and multi-dose completion across patient race/ethnicity, age, gender, distance to first vaccination, and community characteristics. Eligible patients received their first dose of mRNA-1273 administered by Walgreens between December 18, 2020 and February 28, 2022. Variables significantly associated with on-time second dose (all patients) and third dose (immunocompromised patients) in univariate analyses were included in linear regression models. A subset of patients in selected states were studied to identify differences in early and late vaccine adoption.
Results: Patients (N = 4,870,915) who received ≥ 1 dose of mRNA-1273 were 57.0% White, 52.6% female, and averaged 49.4 years old. Approximately 85% of patients received a second dose during the study period. Factors associated with on-time second dose administration included older age, race/ethnicity, traveling ≤ 10 miles for the first dose, higher community-level health insurance, and residing in areas with low social vulnerability. Only 51.0% of immunocompromised patients received the third dose as recommended. Factors associated with third dose administration included older age, race/ethnicity, and small-town residence. Early adopters accounted for 60.6% of patients. Factors associated with early adoption included older age, race/ethnicity, and metropolitan residence.
Conclusion: Over 80% of patients received their on-time second dose of mRNA-1273 vaccine per CDC recommendations. Patient demographics and community characteristics were associated with vaccine receipt and series completion. Novel approaches to facilitate series completion during a pandemic should be further studied.
Keywords: COVID-19; COVID-19 vaccine; Epidemiology; Moderna; Pharmacy; Public health; mRNA Vaccine; mRNA-1273.